The Cure Starts Now has funded $25,084,877 (USD) in pediatric brain cancer research in partnership with the DIPG / DMG Collaborative. This includes 163 grants at over 100 hospitals in 29 countries.




Funding of PBTCF 2022 - $25,000

Amount
$25,000.00
Date
January 2022

Massachusetts General Hospital – $50,000

Amount
$50,000.00
Date
November 2021

Targeted Protein Degradation for DIPG Therapy

CONNECT2007 - $345,794

Amount
$345,794.00
Date
September 2021

Phase I/II Study of Lutathera in Pediatric and Young Adult Patients with Recurrent and/or Progressive High-Grade Central Nervous System (CNS) Tumors and Meningiomas which Express Somatostatin Type 2A Receptors and Demonstrate Uptake on DOTATATE

CONNECT2109A - $705,764

Amount
$705,764.00
Date
September 2021

CONNECT2109A: A molecularly-guided phase II study of ribociclib and everolimus in children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) and high-grade glioma (HGG)

CONNECT Consortium - $278,619

Amount
$278,619.00
Date
September 2021

Immuno-Modulation to Treat Poor-Prognosis Pediatric Brain Tumors

Institute of Cancer Research – $113,747

Amount
$113,747.00
Date
September 2021

Co-Culture Disruptor Screens to Target Cell-Cell Interactions in DMG

Institute of Cancer Research – $498,716

Amount
$498,716.00
Date
September 2021

Translating Mechanism to Patient Benefit for ACVR1-Mutant Diffuse Intrinsic Pontine Glioma (DIPG) - An International Connect Consortium Preclinical / Clinical

Sydney Children’s Hospital – $195,327

Amount
$195,327.00
Date
September 2021

Phase I/II Study of Oral DFMO and AMXT1501 for DIPG/DMG

Children’s Hospital of Colorado – $200,000

Amount
$200,000.00
Date
September 2021

Multimodality, Combination Treatment Strategy for DIPG/DMG

Children's Cancer Institute – $50,000

Amount
$50,000.00
Date
September 2021

Developing Novel Combination Therapies for Diffuse Intrinsic Pontine Glioma

Cincinnati Children's Hospital – $200,000

Amount
$200,000.00
Date
September 2021

Targeting Purine Synthesis and One Carbon Metabolism in DIPG

UPMC Children's Hospital – $50,000

Amount
$50,000.00
Date
September 2021

The Role of QPRT and NAD Pathways in DIPG Treatment Resistance

University of Queensland Diamantina Institute – $100,000

Amount
$100,000.00
Date
September 2021

Innovative Models of the Brain Microenvironment to Identify New Treatments for Medulloblastoma

Duke University Hospital – $50,000

Amount
$50,000.00
Date
September 2021

Identifying Oncolytic Viral Therapy Resistance Mechanisms in Brain Tumors

Funding of PBTCF 2021: PBTC-059 - $25,000

Amount
$25,000.00
Date
January 2021

Phase 1 Trial of Autologous HER2-specific CAR T cells in Pediatric Patients with Refractory or Recurrent Ependymoma